Symbol="ADCT"
AssetType="Common Stock"
Name="ADC Therapeutics SA"
Description="ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland."
CIK="1771910"
Exchange="NYSE"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES, CH"
FiscalYearEnd="September"
LatestQuarter="2023-06-30"
MarketCapitalization="96771000"
EBITDA="-103897000"
PERatio="None"
PEGRatio="None"
BookValue="-0.105"
DividendPerShare="0"
DividendYield="0"
EPS="-2.04"
RevenuePerShareTTM="2.297"
ProfitMargin="-0.983"
OperatingMarginTTM="-0.569"
ReturnOnAssetsTTM="-0.128"
ReturnOnEquityTTM="-3.397"
RevenueTTM="184394000"
GrossProfitTTM="35098000"
DilutedEPSTTM="-2.04"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.115"
AnalystTargetPrice="8.17"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="1.641"
PriceToBookRatio="2.579"
EVToRevenue="0.0382"
EVToEBITDA="-0.0402"
Beta="0.979"
num_52WeekHigh="7.07"
num_52WeekLow="1.15"
num_50DayMovingAverage="1.62"
num_200DayMovingAverage="2.762"
SharesOutstanding="80642000"
DividendDate="None"
ExDividendDate="None"
symbol="ADCT"
open="1.20"
high="1.24"
low="1.16"
price="1.20"
volume="215878.00"
latest_trading_day="2023-08-30"
previous_close="1.17"
change="0.03"
change_percent="2.5641%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="79"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="21"
Volume_recent_avg="454599"
Change_recent_avg="0.01"
Delta_recent_avg="0.13"
Variance_recent_avg="0.07"
Change_ratio_recent_avg="-0.51"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="21"
Aroon_momentum_negative="79"
image_negative_thumbnail_id_1="134"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0042.jpeg"
image_negative_thumbnail_id_2="1113"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0146.jpeg"
image_neutral_thumbnail_id_1="562"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0037.jpeg"
image_neutral_thumbnail_id_2="553"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0046.jpeg"
image_positive_thumbnail_id_1="696"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0012.jpeg"
image_positive_thumbnail_id_2="702"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0006.jpeg"
image_professor_thumbnail_id_1="1189"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0023.jpeg"
image_professor_thumbnail_id_2="1179"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
